BackTransmedics Group Overview
Transmedics Group Inc

Transmedics Group Target Price

See Transmedics Group's analyst price targets ($100) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$89.64

Average Target Price

$101.8513.6% upside

13 analysts in the last 4 months

High: $142 | Low: $65

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-05Robert W. Baird$12236.1% upsideOpen
2026-08-05Canaccord Genuity$956% upsideOpen
2026-08-05Stifel Nicolaus$6527.5% downsideOpen
2026-08-03NeedhamMike Matson$10618.3% upsideOpen
2026-07-28UBS$8010.8% downsideOpen
2026-07-06Evercore ISIDaniel Markowitz$900.4% upsideOpen
2026-06-18Stifel Nicolaus$8010.8% downsideOpen
2026-05-26Stifel NicolausThomas Stephan$7516.3% downsideOpen
2026-05-06Needham$14258.4% upsideOpen
2026-05-06Canaccord GenuityWilliam Plovanic$12438.3% upsideOpen
2026-05-06Piper Sandler$12033.9% upsideOpen
2026-05-06Stifel NicolausThomas Stephan$855.2% downsideOpen
2026-05-06Robert W. BairdDavid Rescott$14056.2% upsideOpen
2026-03-09Stifel Nicolaus$13045% upsideOpen
2025-12-17Canaccord Genuity$14865.1% upsideOpen
2025-12-08Needham$16685.2% upsideOpen
2025-12-02Morgan Stanley$13550.6% upsideOpen
2025-10-30Piper SandlerMatt O'Brien$14056.2% upsideOpen
2025-10-30Canaccord GenuityJason Mills$14764% upsideOpen
2025-10-23Needham$14865.1% upsideOpen
2025-10-13Jefferies$14561.8% upsideOpen
2025-10-07Evercore ISI$15572.9% upsideOpen
2024-12-11Robert W. BairdDavid Rescott$12033.9% upsideOpen
2024-12-11Piper SandlerMatt O'Brien$900.4% upsideOpen
2024-10-29Robert W. BairdJoe Vruwink$15067.3% upsideOpen
2024-10-29Canaccord GenuityJason Mills$10921.6% upsideOpen
2024-10-29NeedhamMike Matson$10921.6% upsideOpen
2024-10-29OppenheimerSuraj Kalia$12539.4% upsideOpen
2024-09-23Robert W. BairdDavid Rescott$200123.1% upsideOpen
2024-09-04Piper SandlerMatt O'Brien$180100.8% upsideOpen
2024-08-21NeedhamMike Matson$208132% upsideOpen
2024-08-01Canaccord GenuityWilliam Plovanic$16988.5% upsideOpen
2024-08-01OppenheimerSuraj Kalia$200123.1% upsideOpen
2024-07-15Morgan StanleyPatrick Wood$14561.8% upsideOpen
2024-07-15Piper SandlerMatt O'Brien$17089.6% upsideOpen
2024-06-03StephensGeorge Sellers$15168.5% upsideOpen
2023-01-06Morgan Stanley$6329.7% downsideOpen
2022-08-03Morgan Stanley$3758.7% downsideOpen
2022-08-02Oppenheimer$4549.8% downsideOpen
2022-07-26Cowen & Co.$4549.8% downsideOpen
2022-06-29Morgan Stanley$3462.1% downsideOpen
2022-06-28Cowen & Co.$3956.5% downsideOpen
2022-05-04Morgan Stanley$2572.1% downsideOpen

Transmedics Group (TMDX) FAQ

Transmedics Group (TMDX) currently reports a target price of $100. Use the charts on this page to explore Transmedics Group's target price history and peer comparisons.

Analysts' average 12-month price target for Transmedics Group is $100, about 13.6% upside from the current share price of $89.64. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $100, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Transmedics Group, and consider following TMDX for alerts when major investors trade the stock.

Transmedics Group is classified in the Healthcare sector. On target price, it currently shows $100. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TMDX with unrelated industries.